GlassScriptPhysician profile
Lori Ann Jackson
NPI 1235695677
$2,102.60
in general payments reported to CMS, 2019-2025
36 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $506 · 2022: $529 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $259.38 | 2021-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $198.74 | 2021-2025 | |
| Amgen INC. | $185.00 | 2021-2025 | Repatha, Otezla |
| Pfizer INC. | $159.31 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $144.41 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $129.56 | 2021-2025 | Jardiance, Kisunla |
| Abbvie INC. | $115.03 | 2021-2025 | |
| Astellas Pharma US INC | $107.19 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $94.18 | 2022-2025 | |
| Corcept Therapeutics | $72.33 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $61.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $56.44 | 2021-2025 | Breztri |
| Novo Nordisk INC | $49.99 | 2022-2025 | Wegovy |
| Avanir Pharmaceuticals, INC. | $48.20 | 2021-2022 | |
| Exact Sciences Corporation | $39.41 | 2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $37.55 | 2025 | Clottriever Bold Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.88 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $26.65 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $23.52 | 2021-2022 | |
| Tonix Medicines, INC. | $22.70 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $20.49 | 2025 | |
| Uswm, LLC | $20.29 | 2021 | |
| Acadia Pharmaceuticals INC | $18.63 | 2022 | |
| Dynavax Technologies Corporation | $16.72 | 2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $16.58 | 2025 | Auvelity |
| Tolmar, INC. | $14.98 | 2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $14.76 | 2025 | NP Thyroid 60 |
| Radius Health, INC. | $14.68 | 2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $14.30 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $14.13 | 2025 | Spravato |
| Dexcom, INC. | $13.89 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.94 | 2021 | |
| Eisai INC. | $12.35 | 2021 | |
| Amarin Pharma, INC. | $11.81 | 2021 | |
| Horizon Therapeutics Plc | $11.32 | 2021 | |
| Metacel Pharmaceuticals LLC | $11.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.